Amuchina and Infasil: agreement reached for the transfer of the brands from Angelini Pharma to Fater

Angelini Pharma, an international pharmaceutical company part of the Angelini Industries Group, and Fater, a 50/50 joint venture between Angelini Industries and Procter & Gamble, a leader in the personal care absorbent products market and a key player in the European home care and tissue products market, announced that they have signed an agreement to transfer the business unit including the Amuchina® and Infasil® brands from Angelini Pharma to Fater. This is a transaction of significant strategic importance for both companies, with the aim of making the most of two historical brands with high market recognition.

The transfer of the Amuchina® and Infasil® brands to Fater, effective as of January 1^st, 2026, includes the involvement of the staff currently predominantly involved in their management, recognizing the value of the skills and experience gained over time. The transaction, which will include the assets related to the two brands, aims to ensure maximum business continuity for the market and customers.

The operation fits into Angelini Pharma's global development strategy of maintaining a focus on Consumer Healthcare and investing in Specialty Care with particular reference to Brain Health. In addition, through the transfer to Fater, the two brands will benefit from new development and growth opportunities thanks to the strong consistency with Fater's operating model and solid positioning in the consumer market.

With the transfer to Fater, Amuchina® and Infasil® will continue to be part of the Angelini Industries Group perimeter. This transaction opens a new phase oriented toward focused management consistent with the highly specialized nature of the consumer market, enhancing the value of two highly recognizable brands.

Read the full press release on angelinipharma.it